Bureau of Justice Assistance - Center for Program Evaluation and Performance Measurement

breadcrumb triangle

breadcrumb triangle

breadcrumb triangle

Measures of Prescription Drug Monitoring Programs Performance

BJA Required Performance Measures

Program Goals	Performance Measure	Data Grantee Provides
1. Reduce the rate of "inappropriate use of prescription drugs.	Process Measures The number of Licensed PRESCRIBERS, DISPENSERS, and INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS that were trained in the use of the state's PDM system.	For this reporting period, how many licensed PRESCRIBERS were trained formally (in a classroom setting) in the use of the PDM system? For this reporting period, how many licensed PRESCRIBERS were trained informally (e.g., via the Internet, mass mailings, and so on) in the use of the PDM system? For this reporting period, how many licensed PRESCRIBERS are there in your state? As of the last day of this reporting period, how many licensed PRESCRIBERS would you say have been trained informally in the use of the system? For this reporting period, how many licensed DISPENSERS were trained formally (in a classroom setting) in the use of the PDM system? For this reporting period, how many licensed DISPENSERS were trained informally (e.g., via the Internet, mass mailings, and so on) in the use of the PDM system? For this reporting period, how many licensed DISPENSERS are there in your state? As of the last day of this reporting period, how many licensed DISPENSERS would you say have been trained informally in the use of the system? For this reporting period, how many INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS were trained formally (in a classroom setting) in the use of the PDM system? For this reporting period, how many INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS were trained informally (e.g., via the Internet, mass mailings, and so on) in the use of the PDM system? For this reporting period, how many INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS are there in your state? As of the last day of this reporting period, how many INDIVIDUALS AUTHORIZED TO CONDUCT INVESTIGATIONS would you say have been trained informally in the use of the system?
	Outcome Measures The number of coroner reports that indicate controlled prescription drug use as the primary or contributing cause of death.	For This Reporting period, how many coroner reports indicated that controlled prescription drug use was the primary or contributing cause of death?
2. Reduce the quantity of pharmaceutical controlled substances obtained by individuals attempting to engage in fraud and deceit (i.e., "doctor shopping").	Process Measures Increase in the number of reports generated.	For Prescribers: For this reporting period, how many how many solicited reports were produced? For this reporting period, how many how many unsolicited reports were produced? For Dispensers: For this reporting period, how many how many solicited reports were produced? For this reporting period, how many how many unsolicited reports were produced? For Individuals Authorized to Conduct Investigations: For this reporting period, how many solicited reports were produced? For this reporting period, how many licensed DISPENSERS are there in your state?
	Outcome Measures The number of individuals that filled prescriptions from multiple pharmacies.	For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II drugs? For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II drugs from 5 or more PRESCRIBERS at 5 or more pharmacies? For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II drugs from 10 or more PRESCRIBERS at 10 or more pharmacies? For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II drugs from 15 or more PRESCRIBERS at 15 or more pharmacies? For this reporting period, how many non-liquid doses of the following were associated with INDIVIDUALS that filled prescriptions for Schedule II drugs: Pain relievers Tranquilizers Stimulants Sedatives For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III drugs? For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III drugs from 5 or more PRESCRIBERS at 5 or more pharmacies? For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III drugs from 10 or more PRESCRIBERS at 10 or more pharmacies? For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III drugs from 15 or more PRESCRIBERS at 15 or more pharmacies? For this reporting period, how many non-liquid doses of the following were associated with INDIVIDUALS that filled prescriptions for Schedule II, III drugs: Pain relievers Tranquilizers Stimulants Sedatives For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III, IV drugs? For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III, IV drugs from 5 or more PRESCRIBERS at 5 or more pharmacies? For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III, IV drugs from 10 or more PRESCRIBERS at 10 or more pharmacies? For this reporting period, how many INDIVIDUALS filled prescriptions for Schedule II, III, IV drugs from 15 or more PRESCRIBERS at 15 or more pharmacies? For this reporting period, how many non-liquid doses of the following were associated with INDIVIDUALS that filled prescriptions for Schedule II, III, IV drugs: Pain relievers Tranquilizers Stimulants Sedatives
3. Increase coordination among PDMP partners (e.g., regulatory, health, law enforcement agencies).	Process Measures The number of licensed PRESCRIBERS and DISTRIBUTORS trained formally in coordinating and sharing data.	How many licensed PRESCRIBERS and DISTRIBUTORS were trained formally in coordination and data sharing? How many PDMP partners were trained in coordination of data sharing?
4. Involve stakeholders in the planning process.	Outcome Measures For planning grantees: Percentage of stakeholder involvement.	Number of stakeholders engaged in the project through memorandums of understanding, meeting attendance, etc. Total number of stakeholders necessary to affect policy change.

Other Possible Performance Measures to Consider (Not Required by BJA)

Program Goals	Performance Measure	Data Grantee Provides
1. Hold monthly PDMP working group meetings	Process Measures Number PDMP working group meetings	Number PDMP working group meetings this reporting period
2. Create standardized reports or queries developed for the PDMP system	Number standardized reports or queries developed for the PDMP system	Number of standardized reports and/ or queries developed for the PDMP system this reporting period
1. Reduce "doctor shopping" incidents by X%	Outcome Measures Change in the number of attempts to obtain prescription drugs through fraud and/or deceit (i.e. "doctor shopping") identified utilizing the PDMP system	Number of attempts to obtain prescription drugs through fraud and/or deceit (i.e. "doctor shopping") each reporting period identified utilizing the PDMP system during each reporting period
1. Reduce "doctor shopping" incidents by X%	Change in the number of persons arrested for obtaining prescription drugs through fraud and/or deceit	Number of persons arrested for obtaining prescription drugs through fraud and/or deceit during each reporting period (according to official police records)
2. Reduce incidents of professional misconduct related to prescription drugs	Change in the number of PRESCRIBERS and DISPENSERS arrested for illegally providing prescription drugs	Number of PRESCRIBERS arrested for illegally prescribing or providing prescription drugs during each reporting period (according to official police records) Number of DISPENSERS arrested for illegally dispensing or providing prescription drugs during each reporting period (according to official police records)
3. Reduce prescription drug abuse by X%	Change in the percentage of prescriptions for addictive drugs (schedules II - V drugs)	Percent of prescriptions for addictive drugs (schedules II-V) during the reporting period
3. Reduce prescription drug abuse by X%	Change in the number of deaths related to prescription drug abuse (schedules II-V)	Number of deaths related to prescription drug abuse (schedules II-V) abuse treatment during the reporting period (according to official coroner records)

| | |
| | |